Exelixis, Inc. (NASDAQ:EXEL) Given Average Recommendation of “Buy” by Analysts

Shares of Exelixis, Inc. (NASDAQ:EXELGet Rating) have been assigned a consensus rating of “Buy” from the nine ratings firms that are currently covering the stock, MarketBeat reports. Seven equities research analysts have rated the stock with a buy rating. The average 12 month target price among analysts that have issued a report on the stock in the last year is $32.29.

Several equities research analysts have issued reports on EXEL shares. Piper Sandler cut their price objective on shares of Exelixis from $34.00 to $30.00 in a research report on Monday, March 14th. TheStreet upgraded shares of Exelixis from a “c” rating to a “b-” rating in a research note on Monday, February 28th. HC Wainwright decreased their target price on shares of Exelixis from $52.00 to $42.00 and set a “buy” rating on the stock in a research report on Friday, February 18th. StockNews.com downgraded shares of Exelixis from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, May 18th. Finally, Jefferies Financial Group assumed coverage on Exelixis in a research report on Thursday, May 12th. They set a “buy” rating and a $28.00 price target on the stock.

In other news, EVP Jeffrey Hessekiel sold 4,717 shares of the business’s stock in a transaction dated Monday, March 28th. The stock was sold at an average price of $22.00, for a total transaction of $103,774.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Jack L. Wyszomierski sold 6,696 shares of Exelixis stock in a transaction that occurred on Monday, April 4th. The stock was sold at an average price of $23.00, for a total transaction of $154,008.00. Following the sale, the director now owns 273,192 shares in the company, valued at $6,283,416. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 80,225 shares of company stock valued at $1,610,649. 2.90% of the stock is owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in the business. CWM LLC lifted its stake in shares of Exelixis by 9.8% in the 1st quarter. CWM LLC now owns 5,137 shares of the biotechnology company’s stock valued at $116,000 after purchasing an additional 460 shares during the period. Quadrant Capital Group LLC lifted its stake in shares of Exelixis by 72.4% in the 1st quarter. Quadrant Capital Group LLC now owns 1,241 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 521 shares during the period. Arizona State Retirement System raised its stake in Exelixis by 0.9% during the 1st quarter. Arizona State Retirement System now owns 85,527 shares of the biotechnology company’s stock worth $1,939,000 after buying an additional 733 shares during the period. Total Clarity Wealth Management Inc. grew its stake in Exelixis by 64.8% in the fourth quarter. Total Clarity Wealth Management Inc. now owns 2,035 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 800 shares during the period. Finally, Crossmark Global Holdings Inc. grew its stake in Exelixis by 2.6% in the first quarter. Crossmark Global Holdings Inc. now owns 31,310 shares of the biotechnology company’s stock valued at $709,000 after acquiring an additional 800 shares during the period. 82.74% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ EXEL opened at $18.14 on Friday. The company has a market capitalization of $5.82 billion, a P/E ratio of 19.72, a P/E/G ratio of 0.58 and a beta of 0.76. Exelixis has a 12 month low of $15.50 and a 12 month high of $23.52. The stock has a 50 day moving average of $20.78 and a 200-day moving average of $19.62.

Exelixis (NASDAQ:EXELGet Rating) last released its quarterly earnings data on Tuesday, May 10th. The biotechnology company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.07. The firm had revenue of $356.00 million during the quarter, compared to analysts’ expectations of $363.22 million. Exelixis had a net margin of 19.60% and a return on equity of 13.77%. The firm’s revenue for the quarter was up 31.7% on a year-over-year basis. On average, equities analysts predict that Exelixis will post 0.89 EPS for the current fiscal year.

About Exelixis (Get Rating)

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Further Reading

Analyst Recommendations for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.